NEW YORK, Nov. 12, 2010 /PRNewswire-FirstCall/ -- Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, will be represented by company CEO, Randall McCoy at the 1st Annual LifeTech Investor Conference at the JW Marriott Marquis today in Miami.
Mr. McCoy will present Regenicin’s core concept and business model for bringing regenerative medicine products to market. Regenicin will be among twenty four public biotechnology and medical technology companies that will be presenting to institutional and private investors.
In addition to Regenicin, the conference will feature the University of Miami Miller School of Medicine Technology Showcase as well as panels of experts from their renowned centers such as the Sylvester Cancer Center, the Bascom Palmer Eye Institute and the Stem Cell Institute. For more information and free registration, visit http://www.LifeTechCapital.com/conference.
About Regenicin
Regenicin, Inc. is a development stage biotechnology company. Regenicin is a publicly traded company, with headquarters in New York. Additional information can be found in the company’s filings with the Securities and Exchange Commission located at www.sec.gov.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company’s current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Regenicin(TM), Inc.
